TG Therapeutics Balance Sheet
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TG Therapeutics financial position
At the end of fiscal 2025, TG Therapeutics reported total assets of $1.06 billion, up 84.1% from a year earlier against total liabilities of $415.2 million. Shareholders' equity stood at $648.0 million, or 60.9% of assets. The company held $79.1 million in cash and equivalents against $245.6 million of debt, a net debt position of $166.5 million.
The current ratio (current assets divided by current liabilities) was 4.10, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.38.
Summary generated from market data by MetaCap's automated system. Methodology
TG Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 79.15M | 179.89M | 92.93M | 102.30M | 298.89M | 553.44M | 112.64M | 41.96M | 56.72M | 25.03M |
| Short-Term Investments | 62.82M | 131.11M | 124.58M | 59.37M | 15.88M | 51.99M | 27.80M | 26.94M | 28.00M | 19.85M |
| Receivables | 305.63M | 129.19M | 51.09M | 0 | 1.39M | — | — | — | — | — |
| Inventory | 125.59M | 110.46M | 39.82M | 0 | — | — | — | — | — | — |
| Total Current Assets | 630.76M | 566.36M | 317.94M | 168.27M | 330.96M | 611.74M | 149.15M | 79.03M | 93.32M | 50.86M |
| Property, Plant & Equipment | — | — | 95.00K | 307.00K | 600.00K | 481.00K | 282.00K | 251.00K | 248.00K | 328.15K |
| Goodwill | — | — | 799.00K | 799.00K | 799.00K | 799.00K | 799.00K | 799.00K | 799.00K | 799.39K |
| Long-Term Investments | 59.14M | 808.00K | 0 | 12.40M | 35.53M | — | — | — | — | 0 |
| Total Assets | 1.06B | 577.69M | 329.59M | 193.57M | 379.63M | 625.64M | 163.01M | 83.62M | 97.38M | 54.78M |
| Accounts Payable | 107.51M | 58.30M | 38.47M | 42.02M | 51.29M | 37.01M | 30.04M | 36.38M | 25.88M | 15.27M |
| Short-Term Debt | — | — | — | 0 | 975.00K | 22.18M | 0 | — | — | — |
| Total Current Liabilities | 153.76M | 90.68M | 53.72M | 53.20M | 65.38M | 87.55M | 84.45M | 38.85M | 27.96M | 16.88M |
| Long-Term Debt | 245.65M | 244.43M | 100.12M | 71.14M | 66.79M | 7.72M | 28.97M | 0 | 0 | 0 |
| Total Liabilities | 415.23M | 355.33M | 169.09M | 134.99M | 142.48M | 106.29M | 124.40M | 59.58M | 30.39M | 18.91M |
| Shareholders' Equity | 648.02M | 222.36M | 160.50M | 58.59M | 237.15M | 519.35M | 38.62M | 24.04M | 66.99M | 35.87M |
| Retained Earnings | -1.08B | -1.53B | -1.55B | -1.53B | -1.33B | -980.60M | -701.22M | -528.35M | -354.86M | -236.39M |
| Total Debt | 245.65M | 244.43M | 100.12M | 71.14M | 67.76M | 29.89M | 28.97M | 0 | 0 | 0 |
| Net Cash (Debt) | -103.67M | 66.57M | 117.39M | 90.54M | 247.00M | 575.53M | 111.47M | 68.90M | 84.72M | 44.88M |
| Shares Outstanding | 155.31M | 155.84M | 151.42M | 146.39M | 143.25M | 140.58M | 109.38M | 83.87M | 73.14M | 56.78M |
This table shows 10 annual periods of TG Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TGTX's reporting calendar. What is a balance sheet?